This guide maps peptides onto the biological sequelae of trauma: BPC-157 for gut and tissue repair, TB-500 and GHK-Cu for tissue and inflammation, Cortexin and Semax for nervous-system recovery, Selank for anxiety. The rationale is mechanistically coherent, but the evidence is almost entirely preclinical or from Russian clinical tradition; only one animal study addresses PTSD-like behaviors directly. No peptide is FDA-approved for any trauma application, and sourcing quality is the main practical risk.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
Can peptides help heal trauma?
Not established. The case is mechanistic: trauma involves gut permeability, neuroinflammation, autonomic dysregulation and tissue damage, and peptides like BPC-157, TB-500 and Semax touch those pathways in animal and cell studies. One animal study showed BPC-157 protected against PTSD-like behaviors. There is no human trial of peptides for psychological trauma.
Which peptides are proposed for trauma recovery?
BPC-157 for gut-brain axis repair and tissue healing, TB-500 and GHK-Cu for tissue and inflammation, the Russian peptides Cortexin, Semax and Selank for nervous-system and anxiety sequelae, and Thymalin for immune dysregulation.2
Is this legal or FDA-approved?
No peptide is FDA-approved for these uses; all are off-label or research-channel. Selank and Semax have Russian clinical studies but limited Western trials, and BPC-157 and TB-500 are WADA-prohibited. Sourcing is the dominant practical risk: impure or mislabeled gray-market product.2
Do peptides replace trauma therapy?
No, and this guide does not claim they do. It frames peptides as biological support alongside somatic therapies like Somatic Experiencing, EMDR and breathwork, which work at the nervous-system level. The peptides' mood and anxiety effects are preclinical or observational.
What would change this rating?
Any human trial of peptides for trauma-related outcomes. Today the closest data are animal neuroprotection studies and the Russian clinical literature.2
Peptides represent a unique intersection of trauma healing and regenerative medicine — they address the physical and neurological sequelae of trauma through systemic signaling restoration, tissue repair, and nervous system modulation. This file covers the primary therapeutic peptides relevant to trauma recovery: BPC-157, TB-500, GHK-Cu, and Khavinson peptides, along with their mechanistic rationale and protocols.
02Overview
Trauma produces effects across multiple biological systems:
| System | Trauma Effect | Peptide Intervention |
|---|---|---|
| Nervous system | Autonomic dysregulation, neuroinflammation, neuroplasticity disruption | BPC-157, Selank, Semax, Khavinson peptides |
| Gut-brain axis | Leaky gut, LPS translocation, serotonin metabolism disruption | BPC-157 (primary), GHK-Cu |
| Musculoskeletal | Soft tissue injury, chronic pain, fascial restriction | BPC-157, TB-500, GHK-Cu |
| Immune | Chronic inflammation, reactivated infections | Thymalin, BPC-157 |
| Mitochondrial | Cellular energy dysfunction, oxidative stress | SS-31 (Elamipretide), BPC-157 |
| Connective tissue | Scar tissue, fascial restriction | BPC-157, TB-500, GHK-Cu |
Swipe table →
The bioregulator peptide approach — restoring proper gene expression and cellular communication — aligns with the somatic therapy principle that healing requires downregulating the threat response and restoring physiological homeostasis.
03BPC-157 (Body Protection Compound)
BPC-157 is a pentadecapeptide (15 amino acids) derived from human gastric juice protein. It is the most studied therapeutic peptide for tissue healing and has significant relevance to trauma recovery.
Mechanisms of Action
| Mechanism | Evidence Level | Relevance to Trauma |
|---|---|---|
| Promotes angiogenesis | Strong — increases VEGF, stabilizes blood vessels | Wound healing, tissue perfusion |
| Upregulates growth hormone receptors | Moderate | Enhanced tissue repair signaling |
| Stabilizes cell membranes | In vitro | Protects against chemical/drug damage |
| Modulates nitric oxide synthase (NOS) | Strong | Vasodilation, wound healing |
| Anti-inflammatory (NF-κB inhibition) | Moderate | Reduces chronic inflammation |
| Fights antibiotic-induced dysbiosis | In vitro + animal | GI protection during stress/treatment |
| Neuroprotective | Preliminary | Central nervous system applications |
| Anxiolytic / anti-depressive | Animal models | Mood effects via serotonin/brain-gut axis |
| Pain modulation | Case reports + animal | Modulates pain pathways |
| Promotes tendon-bone healing | Strong in animal models | Soft tissue repair |
Swipe table →
BPC-157 and the Nervous System
Emerging evidence suggests BPC-157 acts on multiple nervous system targets relevant to trauma:
| Effect | Mechanism | Evidence |
|---|---|---|
| Neuroplasticity enhancement | Promotes neurite outgrowth, neurogenesis | In vitro, animal |
| Serotonin system modulation | May normalize 5-HT transmission | Animal models |
| Brain-gut axis restoration | Heals gut lining, reduces LPS translocation | GI restoration data |
| Dopamine modulation | Some evidence of dopaminergic effects | Animal |
| Reduces neuroinflammation | Anti-inflammatory effects in CNS | Preliminary |
| Protects against PTSD-like behaviors | One animal study showed protective effect | PMID 31411974 |
Swipe table →
Uses
Oral BPC-157: Some practitioners use oral BPC-157 (same dose range) for gut healing; bioavailability is debated but some clinical use exists.
Note: There is no FDA-approved BPC-157 product. It is used off-label or via research/compounding channels.
BPC-157 in Trauma-Informed Contexts
While BPC-157 is not a psychiatric treatment, its effects on the gut-brain axis and neuroplasticity make it relevant to the biological sequelae of trauma:
- Gut healing reduces endotoxin translocation that drives chronic inflammation
- Neuroplasticity enhancement may support the rewiring that therapy requires
- Sleep effects — some users report improved sleep (possibly through gut or serotonin mechanisms)
- Pain reduction — addressing physical pain supports nervous system regulation
04TB-500 (Thymosin Beta-4)
TB-500 is a 43-amino acid peptide that is the naturally occurring form of Thymosin Beta-4, a ubiquitous protein involved in cell migration, tissue repair, and inflammation resolution.
Mechanisms Relevant to Trauma
| Mechanism | Evidence | Relevance to Trauma |
|---|---|---|
| Promotes cell migration (wound healing) | Strong | Tissue repair |
| Anti-inflammatory (upregulates IL-10) | Moderate | Chronic inflammation reduction |
| Cardioprotective | Strong in animal models | Cardiac trauma, post-MI |
| F-actin remodeling | Cell motility, tissue regeneration | Connective tissue repair |
| Angiogenesis promotion | Moderate | Blood supply to healing tissue |
| Stem cell differentiation | Preliminary | Regenerative capacity |
Swipe table →
TB-500 vs. Tβ4 (Same Molecule)
TB-500 is the research-grade designation for Thymosin Beta-4. Both refer to the same 43-amino acid peptide.
05GHK-Cu (Copper Peptide)
GHK-Cu is a tripeptide (glycyl-L-histidyl-L-lysine) that complexes with copper (II) and has broad tissue-protective and regenerative properties.
Mechanisms Relevant to Trauma Healing
| Mechanism | Evidence | Relevance to Trauma |
|---|---|---|
| Wound healing | Strong — upregulates collagen, decorin | Tissue repair |
| Anti-inflammatory | Strong | Chronic inflammation reduction |
| Antioxidant (SOD-like activity) | Moderate | Oxidative stress reduction |
| Skin and connective tissue repair | Strong | Fascia, skin, cartilage |
| Nerve regeneration | Preliminary | Neuropathic pain, nerve injury |
| Anti-anxiety / cognitive effects | Animal data | Nervous system restoration |
| Attracts wound macrophages | Observed | Cleanup phase of healing |
Swipe table →
06Khavinson Peptides for Trauma and Nervous System
The Russian bioregulator peptides developed by Professor Vyacheslav Khavinson have particular relevance to trauma recovery through their effects on nervous system function, tissue repair, and immune regulation.
Cortexin (Brain/Retina Complex)
| Property | Detail |
|---|---|
| Composition | Polypeptide complex from bovine brain/retina |
| Mechanism | Regulates gene expression in brain and retina; neurotrophic activity |
| Clinical use (Soviet) | Stroke recovery, traumatic brain injury, cognitive impairment, retinal degeneration |
| Relevance to trauma | CNS repair, neuroplasticity support |
| Dosing | — |
Swipe table →
Retinalamin
| Property | Detail |
|---|---|
| Composition | Polypeptide complex from bovine retina |
| Mechanism | Tissue-specific bioregulation; retinal cell regeneration |
| Clinical use (Soviet) | Retinal dystrophies, diabetic retinopathy, post-traumatic retinal damage |
| Relevance to trauma | Eye trauma sequelae |
| Dosing | — |
Swipe table →
Chalone
| Property | Detail |
|---|---|
| Composition | Tissue-specific peptide extracts |
| Mechanism | Negative feedback regulation of cell proliferation |
| Clinical use | Wound healing, epithelial maintenance |
| Relevance to trauma | Tissue repair completion; prevents excessive proliferation |
Swipe table →
07Selank and Semax: Nootropic Peptides with Trauma Relevance
Both Selank and Semax are Russian peptides with anxiolytic and cognitive effects that may support trauma recovery by addressing the neuropsychological sequelae of traumatic experiences.
Selank (Tuftsis)
| Property | Detail |
|---|---|
| Composition | Heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) — analogue of human tuftsin |
| Mechanism | Anxiolytic, anti-stress; modulates enkephalin, GABA, serotonin systems |
| Effects | Reduces anxiety (~30-40% in clinical studies), improves mood, no sedation |
| Sleep effects | May normalize sleep patterns |
| Immune modulation | Associated with reduced IL-6, TNF-α |
| Dosing | — |
| PMID | Multiple Russian studies; limited Western RCTs |
Swipe table →
Semax
| Property | Detail |
|---|---|
| Composition | Heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) — ACTH analogue |
| Mechanism | Cognitive enhancement, neurotrophic (BDNF upregulation), neuroprotection |
| Effects | Improved memory, attention, mood; neuroprotection after injury |
| Applications relevant to trauma | Cognitive recovery post-TBI, stroke, chronic fatigue |
| Dosing | — |
| PMID | Multiple Russian studies; PMID 29953325 (BDNF effects) |
Swipe table →
08Uses
Phase 1: Acute/Subacute Trauma (Days 1-30)
Primary goal: Reduce inflammation, support tissue repair, stabilize gut and nervous system
Phase 2: Recovery and Remodeling (Weeks 5-16)
Primary goal: Continue tissue healing, address nervous system dysregulation
Phase 3: Maintenance and Integration (Month 4+)
Primary goal: Sustain gains, support ongoing neuroplasticity and immune function
09Integration with Somatic Therapies
Peptide therapy supports trauma healing at the biological level, while somatic therapies work at the nervous system and experiential level. These approaches are complementary:
| Somatic Approach | Peptide Support Rationale |
|---|---|
| Somatic Experiencing (SE) | SE requires physical activation and discharge; BPC-157 supports tissue healing that may have been stuck |
| EMDR | Neuroplastic enhancement from Semax/Cortexin may support neural rewiring during processing |
| Breathwork | Peptide-driven inflammation reduction supports a less threatened physiology |
| IFS | Cortical and limbic system support from peptides may facilitate parts access |
| TRE | TB-500/GHK-Cu tissue repair may address fascial restrictions underlying tremor patterns |
Swipe table →
Practical Integration
- Foundation: Stabilize gut, reduce systemic inflammation with BPC-157
- Somatic work: While on peptides, engage in body-based trauma therapies
- Nervous system: Add Selank/Semax if significant anxiety/cognitive symptoms persist
- Immunomodulation: Consider Thymalin for persistent immune dysregulation
- Re-evaluate: At 8-12 weeks, assess whether symptoms are shifting
10Notes
- No peptides are FDA-approved for any of these applications; all are used off-label or via research channels
- BPC-157 oral bioavailability is debated; subcutaneous administration is considered most reliable
- Khavinson peptide sourcing is challenging in the West; Russian pharmacies or reputable grey-market sources are typically used
- Peptide quality is critical: Impurities or incorrect sequences can be dangerous; use third-party tested products
- Self-injection protocols require training in sterile technique and subcutaneous/intramuscular injection
- Neuroplasticity timeline: Peptide support for neuroplasticity may take 4-8 weeks to show effects; not an overnight solution
- Mental health claims: Most peptide effects on mood and anxiety are preclinical or observational; not psychiatric treatments per se
11Practical Notes
Peptide Sourcing Considerations
| Source Type | Reliability | Notes |
|---|---|---|
| FDA-approved products (US) | Highest | Very few peptides are approved; BPC-157, TB-500 not among them |
| Compounding pharmacy (US) | Variable | Requires prescription; quality varies by pharmacy |
| Grey market (online) | Low to very low | High risk of impurity, mislabeling |
| Russian pharmacy | Moderate | Authentic but requires translation, shipping |
| Peptide clinics | Variable | Many US clinics offer peptides; quality varies |
Swipe table →
Quality Verification
- Third-party testing (Certificate of Analysis) for purity and identity
- Mass spectrometry confirmation of peptide sequence
- Endotoxin testing for injectable products
- Sterility testing
Injection Basics
| Route | Site | Technique |
|---|---|---|
| Intranasal | Nasal mucosa | Spray or drops into nostril |
Swipe table →
12Connections
13Sources
- PubMed 31411974PubMed 31411974
- PubMed 29953325PubMed 29953325
14Entry history
Latest content update.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.